Biotechnology company Orchard Therapeutics’ OTL-101 has received a promising innovative medicine designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of adenosine deaminase severe combined immunodeficiency.

Commonly known as ADA-SCID or ‘bubble baby’ disease, adenosine deaminase severe combined immunodeficiency is a rare inherited disorder of the immune system.

The disease is caused by mutations in the gene encoding for the adenosine deaminase enzyme, which result in a serious deficiency in white blood cells and lead to life-threatening infections.

OTL-101 is developed by Orchard Therapeutics in collaboration with University College London / Great Ormond Street Hospital (UCL / GOSH) and the University of California, Los Angeles (UCLA).

"With this PIM designation we can potentially make OTL-101 available to UK patients sooner under the EAMS."

The designation indicates that ADA-SCID is a life-threatening condition with high unmet medical need in spite of the currently available treatment options.

Orchard Therapeutics chief scientific officer and UCL / Institute of Child Health Paediatrics professor Bobby Gaspar said: “We are delighted by the designation of OTL-101 as a promising innovative medicine as it recognises the significant unmet need in ADA-SCID, as well as the major potential clinical benefits of OTL-101 over alternative treatment options.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OTL-101’s designation as a promising innovative medicine is the first step of a two-step process, under which the Orchard treatment can benefit from the early access to medicine scheme (EAMS).

Orchard Therapeutics Business Operations senior vice-president Nicolas Koebel said: “With this PIM designation we can potentially make OTL-101 available to UK patients sooner under the EAMS."